Skip to main content

Advertisement

SpringerLink
Log in

Diagnosis and treatment of anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis

  • Forefront Review
  • Section Organizer: Satoshi Kashii, MD, PhD
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

Abstract

Anti-myelin-oligodendrocyte glycoprotein (MOG) antibody positive optic neuritis has been established as a new subset of optic neuropathy. Anti-MOG antibodies are usually measured by cell-based assay. Patients with anti-MOG antibody positive optic neuritis respond well to steroid therapy, and, while visual acuity outcomes are favorable, significant visual field defects remain. Furthermore, patients who are anti-MOG antibody positive have higher rates of recurrence compared to antibody negative patients. Based on these findings, anti-MOG antibody positive patients with optic neuritis have the characteristics of good visual outcomes, residual visual field defects, and high risk of recurrence. Tests for anti-MOG antibody are useful for the diagnosis and treatment of optic neuritis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Modified from reference no.17, Goseki T. Rinsho Ganka (in Japanese) 2017

Fig. 2

Similar content being viewed by others

References

  1. Kezuka T, Usui Y, Goto H. Analysis of the pathogenesis of experimental autoimmune optic neuritis. J Biomed Biotechnol. 2011;2011:294046.

    Article  PubMed  Google Scholar 

  2. Shao H, Huang Z, Sun SL, Kaplan HJ, Sun D. Myelin/oligodendrocyte glycoprotein-specific T-cells induce severe optic neuritis in the C57BL/6 mouse. Invest Ophthalmol Vis Sci. 2004;45(45):4060–5.

    Article  PubMed  Google Scholar 

  3. Linington C, Bradl M, Lassmann H, Brunner C, Vass K. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol. 1988;130:443–54.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. de Kerlero Rosbo N, Honegger P, Lassmann H, Matthieu JM. Demyelination induced in aggregating brain cell cultures by a monoclonal antibody against myelin/ oligodendrocyte glycoprotein. J Neurochem. 1990;55:583–7.

    Article  Google Scholar 

  5. Matsunaga Y, Kezuka T, An X, Fujita K, Matsuyama N, Matsuda R, et al. Visual functional and histopathological correlation in experimental autoimmune optic neuritis. Invest Ophthalmol Vis Sci. 2012;9(53):6964–71.

    Article  Google Scholar 

  6. Lalive PH, Menge T, Delarasse C, Della Gaspera B, Pham-Dinh D, Villoslada P, et al. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc Natl Acad Sci USA. 2006;14(103):2280–5.

    Article  Google Scholar 

  7. Marta CB, Oliver AR, Sweet RA, Pfeiffer SE, Ruddle NH. Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology. Proc Natl Acad Sci USA. 2005;102(27):13992–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Zhou D, Srivastava R, Nessler S, Grummel V, Sommer N, Brück W, et al. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci USA. 2006;103(12):19057–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Kim SM, Woodhall MR, Kim JS, Kim SJ, Park KS, Vincent A, et al. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm. 2015;2(6):e163.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Hacohen Y, Absoud M, Woodhall M, Cummins C, De Goede CG, Hemingway C, et al. Autoantibody biomarkers in childhood-acquired demyelinating syndromes: results from a national surveillance cohort. J Neurol Neurosurg Psychiatr. 2014;85:456–61.

    Article  Google Scholar 

  11. Baumann M, Sahin K, Lechner C, Hennes EM, Schanda K, Mader S, et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatr. 2015;86(265–72):7.

    Google Scholar 

  12. Pröbstel AK, Dornmair K, Bittner R, Sperl P, Jenne D, Magalhaes S, et al. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology. 2011;9(77):580–8.

    Article  Google Scholar 

  13. Horellou P, Wang M, Keo V, Chrétien P, Serguera C, Waters P, et al. Increased interleukin-6 correlates with myelin oligodendrocyte glycoprotein antibodies in pediatric monophasic demyelinating diseases and multiple sclerosis. J Neuroimmunol. 2015;15(289):1–7.

    Article  Google Scholar 

  14. Rostasy K, Mader S, Schanda K, Huppke P, Gärtner J, Kraus V, et al. Anti–myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. Arch Neurol. 2012;69:752–6.

    Article  PubMed  Google Scholar 

  15. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;14(85):177–89.

    Article  Google Scholar 

  16. Pröbstel AK, Rudolf G, Dornmair K, Collongues N, Chanson JB, Sanderson NS, et al. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroinflamm. 2015;12:46–53.

    Article  Google Scholar 

  17. Goseki T. Refractory optic neuritis nation survey in Japan. Rinsho Ganka (in Japanese). 2017;71:1688–90.

    Google Scholar 

  18. Kezuka T, Usui Y, Yamakawa N, Matsunaga Y, Matsuda R, Masuda M, et al. Relationship between NMO-antibody and anti-MOG antibody in optic neuritis. J Neuro-Ophthalmol. 2012;32:107–10.

    Article  Google Scholar 

  19. Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, Takahashi T, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82:474–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Matsuda R, Kezuka T, Umazume A, Okunuki Y, Goto H, Tanaka K. Clinical profile of anti-myelin oligodendrocyte glycoprotein antibody seropositive cases of optic neuritis. Neuro-Ophthalmol. 2015;39:213–9.

    Article  Google Scholar 

  21. Waters P, Woodhall M, O’Connor KC, Reindl M, Lang B, Sato DK, et al. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm. 2015;19(2):e89.

    Article  Google Scholar 

  22. Pache F, Zimmermann H, Mikolajczak J, Schumacher S, Lacheta A, Oertel FC, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflamm. 2016;13:282.

    Article  Google Scholar 

  23. Kezuka T, Tanaka K, Matsunaga Y, Goto H. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;83:475.

    Article  PubMed  Google Scholar 

  24. Miyauchi A, Monden Y, Watanabe M, Sugie H, Morita M, Kezuka T, et al. Persistent presence of the anti-myelin oligodendrocyte glycoprotein autoantibody in a pediatric case of acute disseminated encephalomyelitis followed by optic neuritis. Neuropediatrics. 2014;45:196–9.

    Article  PubMed  Google Scholar 

  25. Akaishi T, Sato DK, Nakashima I, Takeshita T, Takahashi T, Doi H, et al. MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study. J Neurol Neurosurg Psychiatr. 2016;87:446–8.

    Article  Google Scholar 

  26. Akaishi T, Nakashima I, Takeshita T, Mugikura S, Sato DK, Takahashi T, et al. Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica. J Neuroimmunol. 2016;293:28–33.

    Article  CAS  PubMed  Google Scholar 

  27. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K. In cooperation with the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflamm. 2016;13:280.

    Article  Google Scholar 

  28. Martinez-Lapiscina EH, Sepulveda M, Torres-Torres R, Alba-Arbalat S, Llufriu S, Blanco Y, et al. Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders. Ther Adv Neurol Disord. 2016;9:436–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Kidd D, Burton B, Plant GT, Graham EM. Chronic relapsing inflammatory optic neuropathy (CRION). Brain. 2003;126 (Pt 2):276–84.

    Article  Google Scholar 

  30. Chalmoukou K, Alexopoulos H, Akrivou S, Stathopoulos P, Reindl M, Dalakas MC. Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm. 2015;2:e131.

    Article  PubMed  PubMed Central  Google Scholar 

  31. The clinical profile of optic neuritis. Experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Arch Ophthalmol. 1991;109:1673–8.

    Article  Google Scholar 

  32. Wakakura M, Minei-Higa R, Oono S, Matsui Y, Tabuchi A, Kani K, et al. Baseline features of idiopathic optic neuritis as determined by a multicenter treatment trial in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG). Jpn J Ophthalmol. 1999;43:127–32.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Ms. Teresa Nakatani for critical revision of the manuscript. This work was supported in part by Health and Labor Sciences Research Grants for research on intractable diseases from the Ministry of Health, Labour, and Welfare of Japan.

Author information

Authors and Affiliations

  1. KEZUKA Eye Clinic, 1-5-7 Mukojima, Sumida-ku, Tokyo, 131-0033, Japan

    Takeshi Kezuka

  2. Department of Ophthalmology, Tokyo Medical University, Tokyo, Japan

    Takeshi Kezuka

  3. Department of Orthoptics and Visual Science, School of Allied Health Sciences, Kitasato University, Kanagawa, Japan

    Hitoshi Ishikawa

Authors
  1. Takeshi Kezuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hitoshi Ishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takeshi Kezuka.

Ethics declarations

Conflicts of interest

T. Kezuka, None; H. Ishikawa, None.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kezuka, T., Ishikawa, H. Diagnosis and treatment of anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis. Jpn J Ophthalmol 62, 101–108 (2018). https://doi.org/10.1007/s10384-018-0561-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-018-0561-1

Keywords

Search

Navigation